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Protozoal infectionsAbstract Malaria is a disease caused by parasites of the Plasmodium genus, and is one of the most
prevalent diseases in Africa and around the world. Emergency physicians in both endemic and
non-endemic regions often encounter initial presentations of malaria, and knowledge about the
pathophysiology, diagnosis, and treatment of this disease is crucial in caring for these patients. This
article covers brieﬂy the epidemiology of malaria and the lifecycle of the Plasmodium parasite. This
is followed by a discussion of the clinical evaluation, diagnosis, and management of patients with
malaria, as pertinent to the African emergency physician.
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dium. Ce re´sume´ est suivi d’une discussion sur l’e´valuation clinique, le diagnostic et la prise en
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Introduction
One of mankind’s most ancient illnesses, malaria is caused by
parasites of the Plasmodium genus. The most virulent of this
species is Plasmodium falciparum because its case fatality rate
can approach 15–20% even when appropriately treated.1 It
can cause severe organ damage including encephalopathy, re-
nal failure, rapidly developing anemia, pulmonary edema,
and disseminated intravascular coagulation.2 P. falciparum
has developed resistance to multiple anti-malarial drugs over
the past several decades.1 The other three species are Plasmo-
dium ovale, Plasmodium vivax, and Plasmodium malariae.
These species differ in their geographic distribution, are rarely
fatal, and have lower levels of drug resistance, yet still cause
substantial morbidity. P. ovale occurs predominantly in sub-
Saharan Africa, and P. vivax generally occurs throughout
the tropics outside of sub-Saharan Africa.3 P. falciparum and
P. malariae occur globally throughout tropical and subtropical
regions, but are less common than P. falciparum.3 Many casesof malaria, in both endemic and non-endemic regions, present
ﬁrst to emergency departments.4 Patients with malaria can
deteriorate quickly, therefore it is important for emergency
physicians to be able to diagnose and treat the disease.4
Epidemiology
According to the World Health Organization, in 2009 there
were approximately 225 million cases of malaria worldwide,
resulting in 781,000 deaths.5 In 2001, the World Health Orga-
nization ranked malaria as the eighth largest cause of global
disease burden, and the second largest in Africa.6
Over 90% of cases occurred in children under 5 years of age
in Africa.5 The burden of malaria is highest in central and
Western Africa, and in some regions residents are bitten by
at least one infective mosquito per day.1 Warmer temperatures
in some regions of Africa caused by climate change are
thought to contribute to increases in malaria prevalence.7
Plasmodium life cycle
The Plasmodium parasite is transmitted to humans by mosqui-
toes in the Anopheles genus when the insects bite and salivate
into the blood to prevent clotting. The Plasmodium parasites
infect hepatocytes where they rapidly multiply and eventually
lyse their host cells. P. ovale and P. vivax can lie dormant in
the hepatocytes for months to years, potentiating recrudescent
disease at a later time. When released from infected hepato-
cytes, the parasites enter red blood cells (RBCs) and feed on
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the RBCs, causing a new infective parasitemia and repeating
the life cycle. Some parasites become gametocytes. When male
and female gametocytes are both taken up by a biting mos-
quito, they reproduce in the insect, creating progeny ready to
infect a new human host.2
Pathophysiology
The lysis of RBCs by parasites can lead to anemia if the para-
site burden is high. P. falciparum has higher morbidity and
mortality due in part to the production of cell surface proteins
which are expressed on the RBC membrane.8 These cell sur-
face proteins mediate adhesion of the erythrocytes to platelets
and endovascular cells, causing vessel occlusion and down-
stream ischemia.8 Adhesion in the cerebral circulation can
cause cerebral malaria, leading to encephalopathy and sei-
zures; adhesion in placental vasculature can lead to miscar-
riage8; and adhesions in other organs can lead to end organ
damage.
Because repeated infection by the Plasmodium parasites
can lead to partial immunity, most adults in malaria-endemic
areas infrequently become ill from malaria, despite regular
infection. Patients who are most at risk of death and severe ill-
ness from Plasmodium infection are those who have not devel-
oped partial immunity. This includes children under the age of
ﬁve, travelers who have never lived in endemic regions, and
people who had lived in endemic regions in the past with wan-
ing immunity from loss of repeated exposure.8 Additionally,
primigravidae women experience higher rates of placental ma-
laria than multigravidae women because they produce certain
anti-malarial antibodies later in gestation.9
Clinical evaluation of the patient with suspected malaria
Malaria can present with a myriad of non-speciﬁc signs and
symptoms, making the differential diagnosis broad. Symptoms
commonly seen in malaria include fever (92%), chills (79%),
headaches (70%), and diaphoresis (64%).10 The earliest symp-
toms of malaria can also include weakness, myalgias, dizziness,
abdominal pain, diarrhea, nausea, vomiting, anorexia, and
pruritus.11 Symptoms can wax and wane, and may be partially
relieved by symptomatic treatment including ﬂuids and antipy-
retics, so one must be cautious to not use symptomatic
improvement to rule out malaria from the differential.10
Malaria should be considered for all patients presenting with
fevers in endemic regions, especially those not presumed to
have partial immunity. In non-endemic areas, malaria should
be considered for all patients with recent travel histories to
malaria-endemic regions, noting that the incubation period
for P. ovale and P. vivax can vary widely, and may be as much
as several months, especially in patients who have taken
chemoprophylaxis.10
Once diagnosed, further evaluation is merited with a CBC,
electrolytes, coagulation parameters, glucose, hepatic panel,
BUN and creatinine, blood cultures, urinalysis, chest X-ray
and ECG4 to assess for signs of severe malaria (see Table 1).
The parasitemia level is measured by blood smear (see diagnos-
tic methods below), and is particularly important as there is a
correlation between parasitemia and poor prognosis; a 2%
parasitemia corresponds to a 1% mortality rate, whereas a
10% parasitemia correlates to a 50% mortality rate.4Other potential causes of the patient’s symptoms should be
evaluated when appropriate. In the pregnant patient, malaria
can be confused with HELLP syndrome (hemolytic anemia,
elevated liver enzymes, and low platelet count).12 Concurrent
septicemia is rare, occurring in <5% of cases, but should be
considered, and blood cultures should be obtained.13 Likewise,
lumbar puncture should be performed in patients with impaired
consciousness or repeated seizures to rule out meningitis.13
Diagnostic methods
Diagnosis of malaria can be made in several ways. Clinical
diagnosis is the most common diagnostic method, especially
in resource-poor settings where malaria is endemic.11 The Inte-
grated Management of Childhood Illness (IMCI) clinical algo-
rithm for malaria diagnosis was shown to have 100%
sensitivity, but 0–9% speciﬁcity.11 The lack of speciﬁcity in
using clinical diagnosis alone can lead to indiscriminate use
of antimalarials, which increases rates of drug resistance, and
inappropriate treatment of other infectious etiologies.11
Whenever possible, laboratory diagnosis of malaria is pre-
ferred. The most traditional way, still considered the gold stan-
dard, is the thick and thin blood smear, whereby malaria is
diagnosed by visualizing parasites microscopically.2,11 This
technique is simple, low-cost, and allows for speciation, how-
ever requires trained technicians and can have low sensitivity
for low parasite levels.11 Blood smears allow for both specia-
tion based on RBC morphology and quantiﬁcation of parasite
burden.8 With observation of 200 oil immersion ﬁelds, the sen-
sitivity of peripheral blood smears is 90%.10
Another method is the qualitative buffy coat technique,
which stains parasite DNA, and thus detects malaria with ﬂuo-
rescent dyes and microscopy.11 However, it has several disad-
vantages including greater expense, decreased speciﬁcity,11
lack of speciation or quantiﬁcation of parasite burden, and
inability to differentiate malaria from babesia.8 There are also
a large number of rapid diagnostic tests (RDTs) for malaria on
the market, which detect malaria antigens ﬂowing across a
membrane of speciﬁc anti-malarial antibodies.11 RDTs have
been shown to have widely variable sensitivity, and current
recommendations promote their use in conjunction with other
methods, but they have potential for wide use in remote set-
tings without laboratory facilities.1,11
Severe malaria
The emergency physician should evaluate whether a patient
has signs or symptoms of severe malaria since differentiating
uncomplicated from severe malaria will help to guide treat-
ment. In a patient with P. falciparum parasitemia and no other
obvious causes of symptoms, severe malaria is deﬁned as the
presence of any of the clinical or laboratory features listed in
Table 1.
Management
Initial management of the patient with conﬁrmed or suspected
malaria depends upon their clinical stability. There are varying
opinions on when malaria should be treated presumptively,8,10
often depending solely on clinical suspicion. If malaria is con-
ﬁrmed, but speciation cannot be done, patients should be trea-
ted for P. falciparum presumptively.8
Table 1 Assessing for signs of severe malaria.
Evaluation
and tests
Signs of severe malaria
History Failure to feed
More than two seizures in 24 h
Physical exam Impaired consciousness or coma
Prostration (inability to sit or stand)
Kussmaul breathing
Circulatory collapse or shock, systolic blood pressure <70 mmHg in adults or
<50 mm Hg in children
CBC Severe normocytic anemia (Hb < 5 g/dl, packed cell volume <15%)
Electrolytes Metabolic acidosis (plasma bicarbonate <15 mmol/l)
Coagulation
parameters
Abnormal spontaneous bleeding
Glucose Hypoglycemia (blood glucose <2.2 mmol/l or <40 mg/dl)
Hepatic panel Jaundice plus evidence of other vital organ dysfunction
Renal
function tests
Renal impairment (serum creatinine >265 micro mol/l)
Blood smears Hyperparasitemia (>2%/100,000/microliter in low intensity transmission
areas or >5% or 250,000/microliter in areas of high stable malaria
transmission intensity)
Lactate Hyperlactatemia (lactate >5 mmol/l)
Urinalysis Hemoglobinuria
Chest X-ray Pulmonary edema
ECG Evidence of ischemia
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supportive therapy including oral ﬂuid resuscitation, antipyret-
ics, nutrition, and antimalarials as elaborated below. In se-
verely ill patients, hydration status should be monitored with
central venous pressure catheters, and patients with central ner-
vous system involvement may require airway management and
seizure control.4 Patients with severe anemia should receive
RBC transfusion4; however platelet transfusions are usually
not recommended because malaria-induced thrombocytopenia
tends not to be associated with bleeding problems.13 Procoag-
ulant medications should be avoided.8 Patients with acute pul-
monary edema may require supplemental oxygen, diuresis, and
positive pressure ventilation.4 Hypotension and shock should
be treated the same as septic shock, with ﬂuids, vasopressors,
and broad-spectrum antibiotic.4 In capable facilities, red cell
exchange or whole blood exchange transfusion may be consid-
ered for severe malaria, although there are no clinical trials
comparing this therapy with others.8
Parasite levels should be re-measured, preferably by periph-
eral blood smear within 24 h of the initiation of therapy to de-
tect drug resistance and therapeutic failure.8 Effective therapy
should decrease the parasite burden signiﬁcantly.8
Anti-malarial medications
Recommendations for anti-malarial medication regimens are
regularly updated due to changing resistance patterns among
P. falciparum. Emergency physicians unfamiliar with treating
malaria should review guidelines before commencing treat-
ment. Up to date recommendations and dosing can be found
through the WHO.14
The preferred treatment for P. vivax, P. malariae, and
P.ovale (except P. vivax from Indonesia or Papua New Guinea)
remains chloroquine.6,13 Intrahepatic latent forms of P. vivax
and P. ovale can be treated only with primaquine, though this
drug should be avoided in patients with G6PD deﬁcienc.4Uncomplicated malaria can be treated with oral anti-mala-
rials.8 For uncomplicated malaria in children, the WHO rec-
ommends artemesinin-based combination therapy (ACT) in
the face of growing resistance of other previous ﬁrst-line ther-
apies.14 When combined with rapidly-eliminated compounds
such as tetracyclines and clindamycin, ACT should be given
for a 7-day course.14 Combinations with longer-acting drugs
can be prescribed for a 3-day course; these include artemether
plus lumefantrine, artesunate plus amodiaquine, artesunate
plus meﬂoquine, artesunate plus sulfadoxine-pyrimethamine,
and dihydroartemisinin plus piperaquine.14
For severe malaria, the WHO recommends parenteral treat-
ment with IV artesunate for adults and children, in preference
to quinine or quinidine.15 The high doses of quinidine required
to treat malaria can cause hypotension and QT prolongation.12
Quinine can cause cinchonism, a complex of symptoms includ-
ing tinnitus, high tone deafness, nausea, dysphonia, and visual
disturbance.4 Therefore, treatment with IV artesunate is pre-
ferred because it does not require rate-controlled infusion or
cardiac monitoring.14 Patients can be switched to oral agents
after their parasitemia levels are below 1% and they are able
to tolerate PO medications,8 and should continue a full course
of ACT therapy.15
For pregnant women in the ﬁrst trimester, the ﬁrst-line treat-
ment for malaria is quinine plus clindamycin for 7 days, or ACT
if this fails or is unavailable.14 For the second and third trimes-
ters, WHO recommends ACT (except dihydroartemisinin plus
piperaquine), or artesunate plus clindamycin, for 7 days.14 Lac-
tating women should receive the recommended antimalarial
treatments for adults, except primaquine and tetracycline.14
Travelers returning to non-endemic countries with uncom-
plicated malaria should receive atovaquone plus proguanil,
artemether plus lumefantrine, dihydroartemisinin plus
piperaquine, or quinine plus doxycycline (not for children un-
der eight) or clindamycin.14 Severe malaria for travelers should
be treated the same as for endemic patients.14
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Patients who are well-appearing with a normal CBC and hepa-
tic panel may be discharged with follow up on their peripheral
blood smear results.10 Admission is recommended if P. falcipa-
rum is suspected and if the patient is >65 years, pregnant, not
immune to malaria, or if the patient has coexisting medical
conditions.10 All children with conﬁrmed or suspected P. falci-
parum infection should be admitted for at least 24 h because of
the risk of rapid progression of disease.13 Patients with severe
malaria should be admitted to an intensive care unit.10
Future prophylaxis is important and includes measures to
decrease exposure to mosquitoes, including bednets, screened
rooms, and insect repellents, and avoiding walking outside at
night when Anopheles mosquitoes bite.8 For non-immune
travelers anticipating travel to endemic regions, chemoprophy-
laxis is recommended. For chloroquine-resistant areas, chemo-
prophylaxis includes weekly meﬂoquine starting 1 week before
travel to an endemic area and continuing 4 weeks after, or ato-
vaquone and proguanil daily, starting 1–2 days before travel
and ending 1 week afterwards.8 Meﬂoquine can cause neuro-
psychiatric side effects and should be avoided in patients with
epilepsy and psychiatric illnesses.16
Conclusion
Malaria is a widespread disease in Africa and around the
world. Emergency physicians are often the ﬁrst line in medical
management of malaria. Early recognition is important as the
disease can progress quickly. Proper diagnosis and treatment is
also important as part of emergency physicians’ stewardship of
effective therapies in avoiding development of drug resistance
and appropriately treating other diseases on the differential.Contribution
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